Biotechnology News and Research

RSS

Simple and inexpensive method to cut DNA could transform genetic medicine

A simple, precise and inexpensive method for cutting DNA to insert genes into human cells could transform genetic medicine, making routine what now are expensive, complicated and rare procedures for replacing defective genes in order to fix genetic disease or even cure AIDS.

10 Jan 2013

Wockhardt receives final FDA approval for Lamotrigine to treat epilepsy

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 25mg, 50mg, 100mg, 200mg and 300mg extended release tablets of Lamotrigine, which is used in treatment of epilepsy.

9 Jan 2013

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its orally ingested insulin candidate, ORMD-0801.

9 Jan 2013

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced positive, statistically significant data from the Company's Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb (also referred to as SPI-014) in healthy volunteers.

8 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

Researchers identify protein that helps prevent obesity

University of Florida researchers and colleagues have identified a protein that, when absent, helps the body burn fat and prevents insulin resistance and obesity.

8 Jan 2013

Biogen Idec files rFIXFc BLA with FDA for treatment of hemophilia B

Today Biogen Idec announced the company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B.

7 Jan 2013

Rhythm commences RM-493 Phase 2 trial in obesity

Rhythm announced today the initiation of a Phase 2 clinical trial with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity.

7 Jan 2013

Paper provides comprehensive assessment of motor performance after cervical spinal cord injury

More than half of traumatic spinal cord injuries (SCI) in humans are cervical lesions, resulting in chronic loss of limb function. A better understanding of the link between the neurologic damage caused by SCI, spontaneous motor function recovery, and long-term motor deficits would lead to better therapeutic approaches, as discussed in an article in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The

4 Jan 2013

New rat model simulates traumatic or surgical muscle tissue loss in humans

Penetrating soft tissue injuries that may be caused by bullet wounds or motor vehicle accidents, or exposure to explosive devices in military settings, can cause muscle loss resulting in functional disability and cosmetic deformity. Efforts underway to develop tissue engineering solutions to repair and replace damaged and lost muscle will benefit greatly from the availability of robust animal models to test these innovative therapeutic strategies.

4 Jan 2013

Top-line results from Biogen Idec’s dexpramipexole Phase 3 trial on amyotrophic lateral sclerosis

Today Biogen Idec reported top-line results of EMPOWER, a Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis (ALS).

3 Jan 2013

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

3 Jan 2013

No significant difference in patient outcomes with RBC transfusions using lower threshold levels

The level at which red blood cells are transfused, a common treatment in clinical practice, is often deliberated among physicians. Guidelines for blood transfusion levels were only recently issued in March 2012 diminishing some of the debate. Today, in a new section called JAMA Clinical Evidence Synopsis, the Journal of the American Medical Association (JAMA), published a summary of the systematic review of the 19 clinical trials that compare higher versus lower hemoglobin thresholds in red blood cell transfusion.

3 Jan 2013

Kareus announces start of KU-046 Phase I study in Alzheimer's

Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.

3 Jan 2013

UMDNJ-School of Osteopathic Medicine establishes Biomarker Discovery Center

Following recent discoveries by its researchers that could significantly change the diagnosis and treatment of a number of diseases, the University of Medicine and Dentistry of New Jersey (UMDNJ)-School of Osteopathic Medicine has established the Biomarker Discovery Center on its Stratford campus.

3 Jan 2013

EPIRUS’ BOW-015 achieves bioequivalence to Remicade in a single dose comparator trial

EPIRUS Biopharmaceuticals, Inc., formerly known as fourteen22 Inc, announced that its lead asset, BOW-015, achieved bioequivalence to Remicade in a single dose comparator trial.

3 Jan 2013

Whole Genome Mapping and NGS deliver high-quality reference genome of domestic goat

OpGen, Inc. today announced its ARGUS Whole Genome Mapping System technology was used in combination with next-generation sequencing (NGS) to produce the first, high-quality reference genome of the domestic goat.

26 Dec 2012

Acorda Therapeutics acquires Neuronex

Acorda Therapeutics, Inc. today announced that the Company has completed the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition.

21 Dec 2012

MiR-15 contributes to the heart's ability to regenerate following injury

UT Southwestern Medical Center researchers have pinpointed a molecular mechanism needed to unleash the heart's ability to regenerate, a critical step toward developing eventual therapies for damage suffered following a heart attack.

21 Dec 2012

Novel way to design metal organic frameworks under completely liquid-free conditions

Researchers at Aldrich Materials Science, a strategic technology initiative of Sigma-Aldrich Corporation have discovered an innovative way to design an important class of three-dimensional (3D) hybrid structures, Metal Organic Frameworks (MOFs), under completely liquid-free conditions.

20 Dec 2012

Biotechnology News and Research

Simple and inexpensive method to cut DNA could transform genetic medicine

Wockhardt receives final FDA approval for Lamotrigine to treat epilepsy

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

Researchers identify protein that helps prevent obesity

Biogen Idec files rFIXFc BLA with FDA for treatment of hemophilia B

Rhythm commences RM-493 Phase 2 trial in obesity

Paper provides comprehensive assessment of motor performance after cervical spinal cord injury

New rat model simulates traumatic or surgical muscle tissue loss in humans

Top-line results from Biogen Idec’s dexpramipexole Phase 3 trial on amyotrophic lateral sclerosis

Pfizer, Repligen sign licensing deal to advance spinal muscular atrophy program

No significant difference in patient outcomes with RBC transfusions using lower threshold levels

Kareus announces start of KU-046 Phase I study in Alzheimer's

UMDNJ-School of Osteopathic Medicine establishes Biomarker Discovery Center

EPIRUS’ BOW-015 achieves bioequivalence to Remicade in a single dose comparator trial

Whole Genome Mapping and NGS deliver high-quality reference genome of domestic goat

Acorda Therapeutics acquires Neuronex

MiR-15 contributes to the heart's ability to regenerate following injury

Novel way to design metal organic frameworks under completely liquid-free conditions

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News